Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
| Заболевание | Non Alcoholic Steatohepatitis, Fibrosis |
|---|---|
| Фаза | Фаза 1/2 |
| Спонсор | Stanford University |
| Статус | Завершено |
| Участники | 53 участн. |
| Вмешательство | Idebenone |
| Дата начала | 30.07.2021 |
| Дата завершения | 5.07.2023 |
| Публикация результатов | 27.03.2026 |
Кратко
This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and tolerability of Idebenone in patients 18 years of age or older with non-alcoholic steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and fibrosis improvement will be assessed.
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
| Idebenone | 9 Participants |
|---|---|
| Placebo | 4 Participants |
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
- Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
- Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
- Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
- Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.